Recent Finacing
Recent Raise
Celator Pharmaceuticals develops liposome-based CombiPlex fixed-ratio chemotherapy formulations, advancing CPX-351 for AML in Phase 3, CPX-1 for colorectal cancer, and preclinical CPX-571; offices in Princeton and Vancouver.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors